PriceTargets.com logo

Hikma Pharmaceuticals - HIK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 1,725
  • Forecasted Upside: 14.58 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,505.50 As of 11/28/2022 01:00 AM ET
▼ -17.5 (-1.15%)

This chart shows the closing price for HIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIK

Analyst Price Target is GBX 1,725
▲ +14.58% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 1,725, with a high forecast of GBX 2,300 and a low forecast of GBX 1,400. The average price target represents a 14.58% upside from the last price of GBX 1,505.50.

This chart shows the closing price for HIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Hikma Pharmaceuticals. This rating has held steady since November 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2022Berenberg BankReiterated RatingHoldGBX 1,440
11/1/2022BarclaysReiterated RatingEqual WeightGBX 1,400
10/4/2022Berenberg BankReiterated RatingHoldGBX 1,440
9/30/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/31/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/11/2022JPMorgan Chase & Co.Lower TargetNeutralGBX 1,900 ➝ GBX 1,760
8/5/2022BarclaysDowngradeEqual WeightGBX 2,250 ➝ GBX 1,750
8/2/2022BarclaysReiterated RatingOverweightGBX 2,250
7/19/2022BarclaysLower TargetOverweightGBX 2,500 ➝ GBX 2,250
7/4/2022BarclaysReiterated RatingOverweightGBX 2,500
6/1/2022BarclaysReiterated RatingOverweightGBX 2,500
5/25/2022JPMorgan Chase & Co.DowngradeNeutralGBX 2,900 ➝ GBX 1,900
5/24/2022BarclaysReiterated RatingOverweightGBX 2,500
5/11/2022Morgan StanleyReiterated RatingEqual Weight
5/9/2022BarclaysReiterated RatingOverweightGBX 2,800
4/29/2022BarclaysReiterated RatingOverweightGBX 2,800
4/14/2022BarclaysReiterated RatingOverweightGBX 2,800
4/4/2022BarclaysReiterated RatingOverweightGBX 2,800
3/15/2022BarclaysReiterated RatingOverweightGBX 2,800
3/7/2022BarclaysReiterated RatingOverweightGBX 2,800
3/3/2022Morgan StanleyDowngradeEqual WeightGBX 2,800 ➝ GBX 2,300
2/21/2022BarclaysReiterated RatingOverweightGBX 2,800
2/9/2022Morgan StanleyReiterated RatingOverweight
2/9/2022BarclaysLower TargetOverweightGBX 3,000 ➝ GBX 2,800
1/24/2022BarclaysReiterated RatingOverweightGBX 7,000
1/17/2022JPMorgan Chase & Co.Reiterated RatingOverweight
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
12/17/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/1/2021CitigroupReiterated RatingBuyGBX 2,880
10/20/2021BarclaysBoost TargetOverweightGBX 2,900 ➝ GBX 3,000
9/2/2021BarclaysBoost TargetOverweightGBX 2,800 ➝ GBX 2,900
7/19/2021BarclaysReiterated RatingOverweightGBX 2,800
5/6/2021BarclaysReiterated RatingOverweightGBX 2,800
2/1/2021CitigroupReiterated RatingBuy
9/2/2020CitigroupReiterated RatingBuy
7/30/2020Peel HuntBoost TargetBuyGBX 2,380 ➝ GBX 2,860
7/7/2020Morgan StanleyUpgradeOverweightGBX 2,200 ➝ GBX 2,600
7/2/2020Peel HuntReiterated RatingBuy
6/23/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/22/2020Peel HuntReiterated RatingBuy
4/30/2020Peel HuntReiterated RatingBuy
4/28/2020BarclaysBoost TargetEqual WeightGBX 1,950 ➝ GBX 2,200
4/24/2020The Goldman Sachs GroupDowngradeNeutralGBX 2,200 ➝ GBX 2,400
4/24/2020Peel HuntReiterated RatingBuy
4/3/2020CitigroupBoost TargetBuyGBX 2,150 ➝ GBX 2,500
4/2/2020JPMorgan Chase & Co.UpgradeOverweightGBX 1,850 ➝ GBX 2,400
4/2/2020Peel HuntUpgradeBuyGBX 1,990 ➝ GBX 2,380
3/31/2020Peel HuntReiterated RatingHold
3/12/2020Jefferies Financial GroupBoost TargetBuyGBX 2,300 ➝ GBX 2,390
3/10/2020CitigroupUpgradeBuyGBX 1,980 ➝ GBX 2,150
3/5/2020Peel HuntReiterated RatingHold
3/2/2020BarclaysBoost TargetEqual weightGBX 1,900 ➝ GBX 1,950
2/28/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
2/28/2020CitigroupReiterated RatingNeutral
2/24/2020Peel HuntReiterated RatingHold
2/20/2020BarclaysReiterated RatingEqual weight
2/18/2020Peel HuntReiterated RatingHold
2/17/2020CitigroupDowngradeNeutral
2/5/2020Peel HuntReiterated RatingHold
1/27/2020Peel HuntReiterated RatingHold
1/21/2020Jefferies Financial GroupLower TargetBuyGBX 2,310 ➝ GBX 2,240
1/20/2020BarclaysReiterated RatingEqual WeightGBX 1,900
1/10/2020Peel HuntReiterated RatingHold
1/6/2020JPMorgan Chase & Co.Boost TargetNeutralGBX 1,800 ➝ GBX 1,850
12/6/2019BarclaysReiterated RatingEqual weight
12/5/2019Peel HuntReiterated RatingHold
12/3/2019JPMorgan Chase & Co.Boost TargetNeutralGBX 1,700 ➝ GBX 1,800
11/27/2019Peel HuntReiterated RatingHold
11/27/2019HSBCReiterated RatingReduce
11/18/2019BarclaysReiterated RatingEqual weight
11/15/2019Jefferies Financial GroupReiterated RatingBuy
11/13/2019Morgan StanleyReiterated RatingEqual weight
11/7/2019CitigroupReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingHold
9/2/2019Peel HuntReiterated RatingHold
8/20/2019BarclaysBoost TargetEqual weightGBX 1,800 ➝ GBX 1,900
8/9/2019Peel HuntReiterated RatingHoldGBX 1,870 ➝ GBX 2,050
7/29/2019Peel HuntReiterated RatingHold
7/3/2019Peel HuntReiterated RatingHold
6/18/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,700
6/4/2019Peel HuntReiterated RatingHold
5/17/2019Peel HuntReiterated RatingHold
5/3/2019BarclaysReiterated RatingEqual WeightGBX 1,800
5/2/2019Peel HuntReiterated RatingHold
4/10/2019BarclaysReiterated RatingEqual weight
4/2/2019Peel HuntReiterated RatingHold
3/21/2019BarclaysLower TargetEqual weightGBX 1,950 ➝ GBX 1,800
3/19/2019CitigroupUpgradeBuy
3/19/2019Jefferies Financial GroupLower TargetBuyGBX 2,000 ➝ GBX 1,960
3/14/2019HSBCBoost TargetReduceGBX 1,225 ➝ GBX 1,350
3/14/2019JPMorgan Chase & Co.Lower TargetNeutralGBX 1,800 ➝ GBX 1,700
3/13/2019Numis SecuritiesReiterated RatingHoldGBX 1,730
3/12/2019Peel HuntLower TargetHoldGBX 2,000 ➝ GBX 1,870
1/31/2019Peel HuntReiterated RatingHold
1/21/2019BarclaysReiterated RatingEqual weight
1/15/2019BarclaysReiterated RatingEqual weight
1/7/2019Peel HuntReiterated RatingHold
1/2/2019JPMorgan Chase & Co.Lower TargetNeutralGBX 1,900 ➝ GBX 1,800
12/19/2018BarclaysReiterated RatingEqual weight
12/7/2018BarclaysReiterated RatingEqual weight
12/6/2018Peel HuntReiterated RatingHold
11/27/2018Jefferies Financial GroupUpgradeBuyGBX 1,643 ➝ GBX 2,000
11/20/2018JPMorgan Chase & Co.Boost TargetNeutralGBX 1,050 ➝ GBX 1,900
11/12/2018Peel HuntDowngradeHoldGBX 1,950 ➝ GBX 2,000
11/9/2018BarclaysReiterated RatingEqual WeightGBX 1,950
11/8/2018Peel HuntReiterated RatingAdd
11/6/2018BarclaysUpgradeEqual weightGBX 1,400 ➝ GBX 1,800
11/1/2018Peel HuntReiterated RatingAdd
10/30/2018CitigroupReiterated RatingBuyGBX 2,250
10/23/2018Peel HuntReiterated RatingAdd
10/15/2018BarclaysReiterated RatingUnderweight
10/9/2018BarclaysReiterated RatingUnderweight
10/3/2018Peel HuntReiterated RatingAdd
10/3/2018CitigroupBoost TargetBuyGBX 2,100 ➝ GBX 2,250
9/24/2018BarclaysReiterated RatingUnderweight
9/17/2018BarclaysReiterated RatingUnderweight
9/4/2018Peel HuntReiterated RatingAdd
8/24/2018BarclaysReiterated RatingUnderweightGBX 1,400
8/21/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,050
8/20/2018CitigroupBoost TargetBuyGBX 1,675 ➝ GBX 2,100
8/16/2018BarclaysReiterated RatingUnderweight
8/16/2018Peel HuntUpgradeAddGBX 1,160 ➝ GBX 1,950
8/15/2018Numis SecuritiesReiterated RatingHold
8/15/2018Peel HuntReiterated RatingHoldGBX 1,160
8/10/2018BarclaysReiterated RatingUnderweight
8/9/2018Numis SecuritiesDowngradeHoldGBX 1,560
8/1/2018Peel HuntReiterated RatingHold
7/19/2018BarclaysReiterated RatingUnderweight
7/10/2018BarclaysReiterated RatingUnderweight
7/3/2018CitigroupReiterated RatingBuyGBX 1,675
7/3/2018Peel HuntReiterated RatingHold
5/31/2018Peel HuntReiterated RatingHold
5/21/2018BarclaysReiterated RatingUnderweight
5/18/2018Numis SecuritiesDowngradeAddGBX 1,300 ➝ GBX 1,560
5/18/2018Jefferies Financial GroupReiterated RatingHoldGBX 997
5/18/2018Peel HuntReiterated RatingHold
5/1/2018CitigroupBoost TargetBuyGBX 1,250 ➝ GBX 1,475
4/4/2018Peel HuntReiterated RatingHold
3/20/2018Peel HuntLower TargetHoldGBX 1,180 ➝ GBX 1,160
3/19/2018BarclaysReiterated RatingUnderweightGBX 800 ➝ GBX 850
3/15/2018Morgan StanleyBoost TargetEqual weightGBX 1,000 ➝ GBX 1,050
3/15/2018CitigroupUpgradeBuyGBX 1,250
3/15/2018JPMorgan Chase & Co.Boost TargetNeutralGBX 1,000 ➝ GBX 1,050
3/15/2018Jefferies Financial GroupUpgradeHoldGBX 895 ➝ GBX 997
3/14/2018Peel HuntReiterated RatingHoldGBX 1,180
3/14/2018Numis SecuritiesInitiated CoverageBuyGBX 1,300
3/1/2018BarclaysDowngradeUnderweightGBX 1,500 ➝ GBX 800
2/15/2018Peel HuntLower TargetHoldGBX 1,390 ➝ GBX 1,180
2/1/2018Peel HuntReiterated RatingHoldGBX 1,390
1/17/2018Jefferies Financial GroupReiterated RatingUnderperformGBX 895
1/15/2018JPMorgan Chase & Co.Reiterated RatingNeutral
1/10/2018Jefferies Financial GroupDowngradeUnderperformGBX 1,074 ➝ GBX 895
12/20/2017Numis SecuritiesReiterated RatingBuyGBX 1,300
12/4/2017Jefferies Financial GroupBoost TargetHoldGBX 1,045 ➝ GBX 1,074
12/1/2017Morgan StanleyReiterated RatingEqual weightGBX 1,100
(Data available from 11/28/2017 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/30/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 1,505.50
Low: 1,496
High: 1,522.78

50 Day Range

MA: GBX 1,314.44
Low: 1,191
High: 1,523

52 Week Range

Now: GBX 1,505.50
Low: 1,174.50
High: 2,294

Volume

309,916 shs

Average Volume

669,811 shs

Market Capitalization

£3.32 billion

P/E Ratio

1,194.84

Dividend Yield

2.76%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Hikma Pharmaceuticals in the last twelve months: Barclays PLC, Berenberg Bank, JPMorgan Chase & Co., and Morgan Stanley.
View the latest analyst ratings for HIK.

What is the current price target for Hikma Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is GBX 1,725, suggesting a possible upside of 14.3%. Morgan Stanley has the highest price target set, predicting HIK will reach GBX 2,300 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of GBX 1,400 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HIK.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HIK, but not buy more shares or sell existing shares.
View the latest ratings for HIK.

What other companies compete with Hikma Pharmaceuticals?

Other companies that are similar to Hikma Pharmaceuticals include BTG, Dechra Pharmaceuticals, Abcam, Mediclinic International and UDG Healthcare. Learn More about companies similar to Hikma Pharmaceuticals.

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company's listed phone number is +44-20-73992760. The official website for Hikma Pharmaceuticals is www.hikma.com. Learn More about contacing Hikma Pharmaceuticals investor relations.